Medical Treatments

NPR's Audie Cornish speaks with Peter Loftus of The Wall Street Journal about Moderna's history and the fact that it has never received Food and Drug Administration approval for one of its products.

Here's how to self-isolate, what the new quarantine guidance means for your household, and which symptoms signal you need immediate emergency care.

Researchers found that a class of antibodies in a monkey's blood provides protection from COVID-19. If that hold true for humans, a blood test may predict whether a vaccine candidate is working.

Experts say low-risk people in the U.S. will likely be immunized before many high-risk people in poor countries.

The Pfizer-BioNTech COVID-19 vaccine was developed fast. But a leading vaccine expert says its important for consumers to know the companies "haven't cut corners" in the clinical science.

The U.S. government says it will issue a vaccine card and use other tools to help millions of Americans follow through with their immunizations against COVID-19.

Drugmaker Moderna says it has applied to the Food and Drug Administration for emergency use authorization for its coronavirus vaccine. It says data bolster its case the vaccine is safe and effective.

The biotech company has new data reinforcing that its COVID-19 inoculation is safe and effective. Moderna is submitting an application to the FDA requesting emergency use authorization.

After admitting the preliminary results of the clinical trial were a mistake, AstraZeneca is now facing many questions about the coronavirus vaccine it has developed with the University of Oxford.

Hospitals are figuring out how to administer drugs that are designed to treat people with mild to moderate COVID-19 symptoms. The drugs are in short supply, and there is no guarantee they will work.

The medicines from Eli Lilly and Regeneron are infused, a process that can take two hours or longer, including observation for side effects. Staffing is as big an issue as the supply of the drugs.

The government is allocating the first batch of coronavirus vaccines based on population, ignoring a Centers for Disease Control and Prevention proposal to distribute them based on high-risk groups.